BRPI0907532A2 - Anticorpos anti-c5ar humanizados - Google Patents

Anticorpos anti-c5ar humanizados

Info

Publication number
BRPI0907532A2
BRPI0907532A2 BRPI0907532-1A BRPI0907532A BRPI0907532A2 BR PI0907532 A2 BRPI0907532 A2 BR PI0907532A2 BR PI0907532 A BRPI0907532 A BR PI0907532A BR PI0907532 A2 BRPI0907532 A2 BR PI0907532A2
Authority
BR
Brazil
Prior art keywords
humanized anti
c5ar antibodies
c5ar
antibodies
humanized
Prior art date
Application number
BRPI0907532-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Peter Whitfeld
David Zahra
Charles Reay Mackay
Original Assignee
G2 Inflammation Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G2 Inflammation Pty Ltd filed Critical G2 Inflammation Pty Ltd
Publication of BRPI0907532A2 publication Critical patent/BRPI0907532A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0907532-1A 2008-02-20 2009-02-19 Anticorpos anti-c5ar humanizados BRPI0907532A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6653908P 2008-02-20 2008-02-20
PCT/AU2009/000184 WO2009103113A1 (en) 2008-02-20 2009-02-19 HUMANIZED ANTI-C5aR ANTIBODIES

Publications (1)

Publication Number Publication Date
BRPI0907532A2 true BRPI0907532A2 (pt) 2015-07-28

Family

ID=40984994

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907532-1A BRPI0907532A2 (pt) 2008-02-20 2009-02-19 Anticorpos anti-c5ar humanizados

Country Status (14)

Country Link
US (3) US8268972B2 (OSRAM)
EP (2) EP2826791A3 (OSRAM)
JP (2) JP2011515073A (OSRAM)
KR (1) KR20100117120A (OSRAM)
CN (2) CN104193824A (OSRAM)
AU (1) AU2009217224B2 (OSRAM)
BR (1) BRPI0907532A2 (OSRAM)
CA (1) CA2714296A1 (OSRAM)
ES (1) ES2562627T3 (OSRAM)
IL (1) IL207217A (OSRAM)
MX (1) MX2010009190A (OSRAM)
RU (1) RU2010138612A (OSRAM)
WO (1) WO2009103113A1 (OSRAM)
ZA (1) ZA201005348B (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2646792T3 (es) 2002-01-25 2017-12-18 Novo Nordisk A/S Anticuerpos monoclonales contra bucles extracelulares de C5aR
KR20090053899A (ko) * 2006-08-22 2009-05-28 지투 인플레메이션 피티와이 엘티디 개선된 특성을 갖는 항-ｃ５ａｒ 항체
RU2010138612A (ru) * 2008-02-20 2012-03-27 Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR
TW201022288A (en) 2008-06-30 2010-06-16 Novo Nordisk As Anti-human interleukin-20 antibodies
CA2737241C (en) * 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
EP3216462A3 (en) 2010-02-26 2017-12-20 Novo Nordisk A/S Stable antibody containing compositions
DK3345615T3 (da) 2010-03-01 2020-01-20 Bayer Healthcare Llc Optimerede monoklonale antistoffer mod inhibitor af vævsfaktoraktiveringsvejen (tfpi)
KR20130086144A (ko) 2010-05-28 2013-07-31 노보 노르디스크 에이/에스 항체 및 보존제를 포함하는 안정한 다중-투여 조성물
EP2468295A1 (en) 2010-12-21 2012-06-27 Affiris AG Vaccines based on peptides of the complement protein C5a
RU2616881C2 (ru) 2011-06-06 2017-04-18 Ново Нордиск А/С Терапевтические антитела
WO2014015133A1 (en) 2012-07-19 2014-01-23 National Cheng Kung University Treatment of osteoarthritis using il-20 antagonists
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
GB201220242D0 (en) * 2012-11-09 2012-12-26 Fusion Antibodies Ltd Antibody
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
WO2014180961A1 (en) * 2013-05-08 2014-11-13 Novo Nordisk A/S Use of c5ar antagonists
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
CA3225091A1 (en) 2014-05-05 2015-11-12 Regeneron Pharmaceuticals, Inc. Humanized c5 and c3 animals
SMT202000438T1 (it) 2014-11-17 2020-09-10 Regeneron Pharma Metodi per trattamento di tumore usando l'anticorpo bispecifico cd3xcd20
RU2698205C2 (ru) * 2014-12-18 2019-08-23 Ф. Хоффманн-Ля Рош Аг Способ определения антител, вызывающих комплемент-зависимую цитотоксичность
PL3277725T3 (pl) 2015-03-30 2021-06-14 Regeneron Pharmaceuticals, Inc. Regiony stałe łańcucha ciężkiego o zmniejszonym wiązaniu do receptorów Fc gamma
CN107849133B (zh) 2015-05-04 2022-08-23 西托姆克斯治疗公司 抗cd166抗体、可活化抗cd166抗体及其使用方法
CN106957366B (zh) * 2016-01-12 2022-02-01 上海昀怡健康科技发展有限公司 一种C5aR抗体及其制备方法和应用
JP7251792B2 (ja) * 2017-03-23 2023-04-04 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗Ｃ５ａ抗体とその使用
BR112020000766A2 (pt) * 2017-07-14 2020-07-21 Cytomx Therapeutics, Inc. anticorpos anti-cd166 e seus usos
JP6511200B1 (ja) * 2017-12-14 2019-05-15 硬化クローム工業株式会社 冷却ロール、およびそれを用いた熱可塑性樹脂シートの製造方法
JP2021527062A (ja) * 2018-06-07 2021-10-11 ケモセントリックス，インコーポレイティド ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果
LT3844189T (lt) 2018-08-31 2025-02-25 Regeneron Pharmaceuticals, Inc. Cd3/cd20 bispecifinių antikūnų dozavimo strategija, mažinanti citokinų išsiskyrimo sindromą
CN109439662B (zh) * 2018-11-15 2020-09-01 北京大学第三医院 用于C5aR1基因敲除的sgRNA、载体以及构建方法和检测方法
BR112021017860A2 (pt) * 2019-03-14 2021-12-07 Morphosys Ag Anticorpo ou fragmento de anticorpo isolado específico para c5ar de humano, composição de ácido nucleico, composição de vetor, célula hospedeira e composição farmacêutica
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
US11912781B2 (en) 2021-01-13 2024-02-27 Visterra, Inc. Humanized complement 5A receptor 1 antibodies and methods of use thereof
CN121152813A (zh) * 2023-03-23 2025-12-16 恺兴生命科技(上海)有限公司 细胞免疫疗法的组合物和方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en) 1972-03-30 1974-06-18 Scott Paper Co Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4568649A (en) 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
JPH02262599A (ja) 1989-01-03 1990-10-25 Merck & Co Inc ヒト多形核白血球からの精製Ｃ５ａレセプター
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5284746A (en) 1990-02-08 1994-02-08 Zymogenetics, Inc. Methods of producing hybrid G protein-coupled receptors
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
US5844094A (en) 1992-09-25 1998-12-01 Commonwealth Scientific And Industrial Research Organization Target binding polypeptide
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US5480974A (en) 1993-06-18 1996-01-02 The Scripps Research Institute Antibodies to human C5a receptor
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5861272A (en) 1995-06-02 1999-01-19 Human Genome Sciences, Inc. C5A receptor
JPH08109200A (ja) 1994-08-19 1996-04-30 Takeda Chem Ind Ltd 抗Ｃ５ａレセプター抗体、その製造法および用途
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
WO1996039511A2 (en) 1995-06-05 1996-12-12 Incyte Pharmaceuticals, Inc. A C5a-LIKE SEVEN TRANSMEMBRANE RECEPTOR
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
WO1998033908A1 (en) 1997-01-31 1998-08-06 Incyte Pharmaceuticals, Inc. Human c5a-like receptor
JP2002505574A (ja) 1997-04-30 2002-02-19 エンゾン，インコーポレイテッド ポリアルキレンオキシド修飾された単鎖ポリペプチド
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
WO2002038767A2 (en) 2000-11-07 2002-05-16 Genetics Institute, Llc. G protein-coupled receptor protein and nucleic acid molecules and uses therefor
AU2002246733B2 (en) 2000-12-19 2007-09-20 Altor Bioscience Corporation Transgenic animals comprising a humanized immune system
WO2002061087A2 (en) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
ATE453661T1 (de) 2001-09-27 2010-01-15 Merck & Co Inc Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodieren, damit verwandte, nichthumane transgene tiere und assayverfahren
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
ES2646792T3 (es) 2002-01-25 2017-12-18 Novo Nordisk A/S Anticuerpos monoclonales contra bucles extracelulares de C5aR
JP2006513702A (ja) 2002-09-09 2006-04-27 ヌラ インコーポレーティッド Ｇタンパク質共役受容体およびその使用
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
JP2007534631A (ja) 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
WO2005060739A1 (en) 2003-12-24 2005-07-07 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
CN1997384A (zh) * 2004-03-26 2007-07-11 普罗米克斯有限公司 使用补体C5a受体调节剂治疗神经系统病症
MX2007011064A (es) 2005-03-23 2008-02-19 Genmab As Anticuerpos contra cd38 para tratamiento de mieloma multiple.
US7649951B2 (en) 2006-08-16 2010-01-19 Harris Corporation System and method for communicating data using symbol-based randomized orthogonal frequency division multiplexing (OFDM) with applied frequency domain spreading
KR20090053899A (ko) 2006-08-22 2009-05-28 지투 인플레메이션 피티와이 엘티디 개선된 특성을 갖는 항-ｃ５ａｒ 항체
EP2061812A4 (en) 2006-08-22 2010-06-09 G2 Inflammation Pty Ltd METHOD FOR THE PRODUCTION OF ANTIBODIES
WO2008030564A2 (en) 2006-09-08 2008-03-13 Verenium Corporation Aglycosylated antibodies and methods of making and using those antibodies
WO2009053368A1 (en) 2007-10-22 2009-04-30 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
RU2010138612A (ru) 2008-02-20 2012-03-27 Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR
WO2010000864A1 (en) 2008-07-04 2010-01-07 Novo Nordisk A/S Method for producing monoclonal antibodies
EP3216462A3 (en) 2010-02-26 2017-12-20 Novo Nordisk A/S Stable antibody containing compositions
KR20130086144A (ko) 2010-05-28 2013-07-31 노보 노르디스크 에이/에스 항체 및 보존제를 포함하는 안정한 다중-투여 조성물

Also Published As

Publication number Publication date
US20120315275A1 (en) 2012-12-13
ZA201005348B (en) 2011-10-26
AU2009217224B2 (en) 2014-09-11
US8268972B2 (en) 2012-09-18
JP2011515073A (ja) 2011-05-19
US8361468B2 (en) 2013-01-29
EP2254911A1 (en) 2010-12-01
ES2562627T3 (es) 2016-03-07
IL207217A (en) 2015-03-31
US20110190477A1 (en) 2011-08-04
US8808701B2 (en) 2014-08-19
CN101970494A (zh) 2011-02-09
JP6034826B2 (ja) 2016-11-30
RU2010138612A (ru) 2012-03-27
US20130129721A1 (en) 2013-05-23
WO2009103113A1 (en) 2009-08-27
CN101970494B (zh) 2015-01-21
CA2714296A1 (en) 2009-08-27
AU2009217224A1 (en) 2009-08-27
IL207217A0 (en) 2010-12-30
JP2014193164A (ja) 2014-10-09
MX2010009190A (es) 2010-09-10
CN104193824A (zh) 2014-12-10
KR20100117120A (ko) 2010-11-02
EP2254911B1 (en) 2015-11-25
EP2826791A2 (en) 2015-01-21
EP2254911A4 (en) 2011-10-19
EP2826791A3 (en) 2015-07-29

Similar Documents

Publication Publication Date Title
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
CR20170001A (es) Anticuerpos anti factor d humanizados
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
BRPI0923359A2 (pt) Anticorpos anti-igf
BRPI0907237A2 (pt) Anticorpo anti-cldn6
HRP20171011T1 (hr) ANTI-eMET ANTITIJELO
BRPI0819165A2 (pt) Anticorpos anti-vegf
DK2131860T3 (da) Anti-sclerostin-antistoffer
DK2344537T3 (da) Bispecifikke anti-vegf/anti-ang-2-antistoffer
SMT201700083B (it) Anticorpi monoclonali
PT2195026E (pt) Anticorpos anti-esclerostina
EP2337798A4 (en) SPECIFIC ANTIBODIES OF THE ASB
PT2406284T (pt) Anticorpos anti-bcma
DK2521736T3 (da) Humaniserede antistoffer
NO344963B1 (no) Humanisert antistoff
BRPI0821777A2 (pt) Anticorpos biespecíficos bivalentes
SG10201601279SA (en) Monoclonal Antibody STRO-4
BRPI1011005A2 (pt) anticorpos anti-epcam
EP2331579A4 (en) MONOCLONAL ANTIBODIES
DK2459167T3 (da) SUBKUTAN ANTI-HER2-antistofformulering
BRPI0922800A2 (pt) anticorpos c-met
HRP20181360T1 (hr) Anti-cd28 humanizirana protutijela
IL221408B (en) Monoclonal antibodies against c-met
EP2349331A4 (en) HUMANIZED ANTIBODIES TO IL-6

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]